Latest Audeara (ASX:AUA) News

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

Audeara Limited has landed its maiden purchase order for hearing aid technology in China, marking a pivotal step in its global expansion with production and launch planned for the final quarter of 2025.

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

Audeara Limited reports a strong start to FY26 with a 46% revenue increase driven by Australian wholesale growth and a key international partnership. The company’s global ambitions are further highlighted by multiple export award nominations.

Audeara Limited has secured a five-year licensing agreement with Eastech (Huizhou) Co., Ltd. to bring its advanced hearing technology to China’s booming medical device market, leveraging major e-commerce platforms for distribution.

Audeara Ltd has reported a landmark FY25 with record cash receipts of $4.9 million, driven by strong domestic sales and expanding global technology partnerships. The company’s strategic R&D and inventory build set the stage for further growth in FY26.

Audeara Limited has reported record unaudited revenue of $3.64 million for the first 11 months of FY25, marking a 14% increase over FY24 and driven by new product launches and international partnerships.

Audeara Limited has landed a significant US$917,000 follow-up purchase order from a global music instrument manufacturer, reinforcing the commercial viability of its hearing technology and expanding its licensing footprint.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.

Audeara has officially launched its Clinico Sound Earbuds CS1 in Taiwan through a strategic partnership with Clinico Inc., marking a key step in its international expansion and tapping into a growing hearing health market.